

Product datasheet for TL304907

OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

Dopamine D2 Receptor (DRD2) Human shRNA Plasmid Kit (Locus ID 1813)

Product data:

Product Type: shRNA Plasmids

Product Name: Dopamine D2 Receptor (DRD2) Human shRNA Plasmid Kit (Locus ID 1813)

Locus ID: 1813

Synonyms: D2DR; D2R

Vector: pGFP-C-shLenti (TR30023)

E. coli Selection: Chloramphenicol (34 ug/ml)

Mammalian Cell

Puromycin

Selection:

Format: Lentiviral plasmids

Components: DRD2 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector(Gene ID = 1813).

5µg purified plasmid DNA per construct

29-mer scrambled shRNA cassette in pGFP-C-shLenti Vector, TR30021, included for free.

RefSeq: BC021195, NM 000795, NM 016574, NM 000795.1, NM 000795.2, NM 000795.3,

NM 016574.1, NM 016574.2, NM 016574.3, NM 000795.4

UniProt ID: P14416

Summary: This gene encodes the D2 subtype of the dopamine receptor. This G-protein coupled receptor

inhibits adenylyl cyclase activity. A missense mutation in this gene causes myoclonus

dystonia; other mutations have been associated with schizophrenia. Alternative splicing of this gene results in two transcript variants encoding different isoforms. A third variant has been described, but it has not been determined whether this form is normal or due to

aberrant splicing. [provided by RefSeq, Jul 2008]

shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To

be certain that your variant of interest is targeted, please contact <u>techsupport@origene.com</u>. If you need a special design or shRNA sequence, please utilize our <u>custom shRNA service</u>.



Performance Guaranteed:

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).